Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately. Dr. Hammond is a nationally recognized leader ...